PDE2A and glioblastoma: Our findings revealed significant downregulation of PDE2A protein levels in hepatocellular carcinoma (HCC), BRCA, LUAD, LUSC, head and neck squamous cell carcinoma (HNSC), GBM, clear cell renal cell carcinoma (CCRCC) and UCEC, as shown in Figure 2C.